 |
|
Febrile neutropenia
Focusing on malignant tumors in childhood itself.
An open, prospective and controlled study undertaken at the Second Pediatric Department at Semmelweis University in Budapest by Prof. György Fekete, M.D., while not investigating Avemar's anti-tumour or supportive effect, demonstrated its ability to prevent the development of a considerable number of febrile neutropenia episodes in children treated with intensive chemotherapy for solid tumours.
Patients enrolled in the study: 22 (in 11 allocated pairs). Aspects of allocation: histologically matching tumour types, same amount of time between diagnosis and enrollment, age, sex, stage.
Follow-up period: 3 years
One group received Avemar + chemoterapy, the other chemotherapy alone. In proportion to the chemotherapy cycles delivered, the number of febrile neutropenia episodes in Avemar-treated group was significantly lower (24% vs.43.3%, p<0.01). The reduction of relative risk was (RRR) -43. The successful suppression of a life-threatening complication is of special importance and can be taken as clinical proof of Avemar's immuno-modulant effect and promotion of bone marrow regeneration.
|
 |
|
 |
